Brandes AA et al. - In a review of the state of treatment of glioblastoma (GBM) in adults, it is clear that GBM is the most malignant among astrocytic tumours and is associated with a poor prognosis Methods
Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter, and extent of surgery constitute the main prognostic factors
Surgery aimed at complete resection should be the first therapeutic modality in the management of glioblastoma
Complete resection is virtually impossible due to infiltrative nature of this disease and relapse is almost inevitable
Results
Postoperative concomitant chemoradiation is the standard treatment and consists of 60 Gy of external-beam radiotherapy plus temozolomide (TMZ) administered concomitantly (75 mg/m2 daily) and after radiotherapy (150–200 mg/m2, for 5 days every 4 weeks)
At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for pts without progression during prior temozolomide treatment
See all
